Loading…
Clinical-stage biotech developing drugs that target RAS-mutant cancers, a historically 'undruggable' driver of many tumors.
Clinical-stage biotech developing drugs that target RAS-mutant cancers, a historically 'undruggable' driver of many tumors.
Has no approved product, so spending is funded by share sales and financing deals rather than by sales. Its lead candidates, RAS(ON) inhibitors, are in late-stage trials in pancreatic cancer and other tumours, and trial results and regulatory decisions are the events that drive its value.
Moat: narrow (IP / patents, process know-how). Proprietary chemistry targeting RAS proteins directly, a target class most rivals could not previously drug.
Headquarters: Redwood City, California, United States · Founded: 2014 · Employees: 883
Size Revolution Medicines (RVMD) is a United States Health Care company (Pharmaceuticals: Other) with a market value of $41.2B, the 293rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $192.28 on 6 Nov 2026.
Performance Over six months the shares gained 35.6%, against -4.4% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Credit Revolution Medicines has 1 bond outstanding ($500M).
Short interest Short interest is 6.0% of the free float (15 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $11.6M | $35.4M |
| Revenue growth | — | — | -100% | -67% | — |
| Gross profit | -$18.1M | -$16.6M | -$11.8M | $2.27M | $25.7M |
| EBITDA | -$1.61B | -$1.17B | -$678M | -$478M | -$249M |
| Net income | -$1.77B | -$1.13B | -$600M | -$436M | -$249M |
| Free cash flow | -$1.23B | -$914M | -$568M | -$358M | -$235M |
| Capital expenditure | $9.10M | $16.0M | $10.3M | $7.73M | $10.8M |
| Total debt | $1.19B | $427M | $136M | $87.9M | $64.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Revolution Medicines RVMD | $41.2B | +36% | n/a | n/a | n/a | n/a |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 15.2× | 5.9% |
| Erasca ERAS | $5.04B | +42% | n/a | n/a | n/a | n/a |
| Verastem VSTM | $1.02B | +72% | +3,996% | -183% | 11.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RVMD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.2% | +2.2% | 11th highest of 21 |
| 6-month return | +35.6% | -4.4% | 3rd highest of 21 |
| Distance from 52-week high | -14.3% | -21.3% | 7th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Revolution Medicines RVMD | United States | $41.2B | +36% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang NHU 002001.SZ | China | $12.3B | -23% | +11% | 33% | 3.1× | -7.8% | +16.7% |
| Cipla CIPLA.NS | India | $12.1B | +4% | -1% | 13% | 3.8× | 28.2% | +8.1% |
| Aurobindo Pharma AUROPHARMA.NS | India | $10.9B | +22% | +14% | 15% | 2.8× | 21.0% | +6.3% |
| Lupin LUPIN.NS | India | $9.65B | -19% | +24% | 24% | 2.9× | 8.8% | +13.0% |
| Abivax ABVX.PA | France | $7.58B | -25% | n/a | n/a | n/a | n/a | n/a |
| Dong-E-E-Jiao 000423.SZ | China | $4.80B | -8% | +8% | 29% | 3.6× | -4.6% | +14.5% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $4.02B | -6% | +32% | 21% | 3.1× | -3.2% | -2.2% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.13B | +35% | -14% | 9% | 9.3× | 34.7% | +5.9% |
| Bausch Health Companies BHC.TO | Canada | $3.09B | +48% | +10% | 27% | 2.0× | -14.5% | +5.9% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $3.02B | -9% | -4% | -13% | 8.6× | 5.2% | +1.0% |
| By-health 300146.SZ | China | $2.61B | -1% | +10% | 11% | 2.0× | 5.1% | +0.6% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.50B | -10% | -1% | 13% | 1.6× | -8.3% | +5.3% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 3.9× | -2.5% | +11.6% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 3.3× | 23.5% | +10.6% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 1.3× | -3.0% | +4.4% |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | 0.6× | -0.8% | -2.1% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | 3.6× | 5.3% | +10.4% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | 4.2× | -1.1% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 1.0× | -6.7% | +3.9% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 3.4× | 4.5% | +60.2% |
Revolution Medicines has 1 bond outstanding with $500M face value.